These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 33325523)

  • 1. Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry.
    Agrawal M; Brenner EJ; Zhang X; Modesto I; Woolcott J; Ungaro RC; Colombel JF; Kappelman MD
    Inflamm Bowel Dis; 2021 Mar; 27(4):585-589. PubMed ID: 33325523
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of tofacitinib in the treatment of inflammatory bowel disease.
    Weisshof R; Golan MA; Yvellez OV; Rubin DT
    Immunotherapy; 2018 Aug; 10(10):837-849. PubMed ID: 29701124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of tofacitinib in IBD: A tricky puzzle.
    Beaugerie L
    United European Gastroenterol J; 2024 Jul; 12(6):658-659. PubMed ID: 38761370
    [No Abstract]   [Full Text] [Related]  

  • 4. The use of Tofacitinib in the treatment of inflammatory bowel disease.
    Nasonov EL; Abdulganieva DI; Fairushina IF
    Ter Arkh; 2019 Mar; 91(2):101-108. PubMed ID: 31094180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines.
    Danese S; Grisham M; Hodge J; Telliez JB
    Am J Physiol Gastrointest Liver Physiol; 2016 Feb; 310(3):G155-62. PubMed ID: 26608188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of routinely collected electronic health records data to support effectiveness evaluations in inflammatory bowel disease: a pilot study of tofacitinib.
    Rudrapatna VA; Glicksberg BS; Butte AJ
    BMJ Health Care Inform; 2021 May; 28(1):. PubMed ID: 34011632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment.
    Vuitton L; Koch S; Peyrin-Biroulet L
    Curr Drug Targets; 2013 Nov; 14(12):1385-91. PubMed ID: 23627915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 outcomes in patients with inflammatory bowel diseases in Latin America: Results from SECURE-IBD registry.
    Queiroz NSF; Martins CA; Quaresma AB; Hino AAF; Steinwurz F; Ungaro RC; Kotze PG
    J Gastroenterol Hepatol; 2021 Nov; 36(11):3033-3040. PubMed ID: 34151470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK inhibition in inflammatory bowel disease.
    Olivera P; Danese S; Peyrin-Biroulet L
    Expert Rev Clin Immunol; 2017 Jul; 13(7):693-703. PubMed ID: 28164724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry.
    Agrawal M; Brenner EJ; Zhang X; Colombel JF; Kappelman MD; Ungaro RC; ; Gearry RB; Kalpan GG; Kissous-Hunt M; Lewis JD; Ng SC; Rahier JF; Reinisch W; Ruemmele FM; Steinwurz F; Underwood FE
    J Crohns Colitis; 2021 May; 15(5):860-863. PubMed ID: 33232456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging Therapies for Inflammatory Bowel Disease.
    Weisshof R; El Jurdi K; Zmeter N; Rubin DT
    Adv Ther; 2018 Nov; 35(11):1746-1762. PubMed ID: 30374806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tofacitinib in Acute Severe Ulcerative Colitis-A Real-World Tertiary Center Experience.
    Honap S; Pavlidis P; Ray S; Sharma E; Anderson S; Sanderson JD; Mawdsley J; Samaan MA; Irving PM
    Inflamm Bowel Dis; 2020 Oct; 26(11):e147-e149. PubMed ID: 32566937
    [No Abstract]   [Full Text] [Related]  

  • 13. Next generation of small molecules in inflammatory bowel disease.
    Olivera P; Danese S; Peyrin-Biroulet L
    Gut; 2017 Feb; 66(2):199-209. PubMed ID: 27856614
    [No Abstract]   [Full Text] [Related]  

  • 14. Tofacitinib for Rescue Therapy in Acute Severe Ulcerative Colitis: A Real-world Experience.
    Kotwani P; Terdiman J; Lewin S
    J Crohns Colitis; 2020 Jul; 14(7):1026-1028. PubMed ID: 32020189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From the American Epicenter: Coronavirus Disease 2019 in Patients with Inflammatory Bowel Disease in the New York City Metropolitan Area.
    Axelrad JE; Malter L; Hong S; Chang S; Bosworth B; Hudesman D
    Inflamm Bowel Dis; 2021 Apr; 27(5):662-666. PubMed ID: 32578843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes.
    Panés J; Su C; Bushmakin AG; Cappelleri JC; Mamolo C; Healey P
    BMC Gastroenterol; 2015 Feb; 15():14. PubMed ID: 25651782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK Inhibitors: Back to Small Molecules for the Treatment of IBD.
    Panés J; Vermeire S
    J Crohns Colitis; 2020 Aug; 14(Supplement_2):S711-S712. PubMed ID: 32737980
    [No Abstract]   [Full Text] [Related]  

  • 18. A machine learning approach identifies 5-ASA and ulcerative colitis as being linked with higher COVID-19 mortality in patients with IBD.
    Roy S; Sheikh SZ; Furey TS
    Sci Rep; 2021 Aug; 11(1):16522. PubMed ID: 34389789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
    De Vries LCS; Wildenberg ME; De Jonge WJ; D'Haens GR
    J Crohns Colitis; 2017 Jul; 11(7):885-893. PubMed ID: 28158411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tofacitinib Therapy, the Lender of Last Resort.
    Rutka M; Pigniczki D; Molnár T
    J Crohns Colitis; 2021 Apr; 15(4):694. PubMed ID: 32978625
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.